rs10455872 — LPA

The Lp(a) Risk Variant — A Major Genetic Determinant of Heart Disease

The LPA gene encodes apolipoprotein(a)¹¹ apolipoprotein(a)
the protein component that distinguishes lipoprotein(a) from regular LDL cholesterol, and rs10455872 is one of the most powerful genetic predictors of cardiovascular disease identified to date. Located in intron 25 of the LPA gene²² intron 25 of the LPA gene
a non-coding region that influences gene expression through unknown mechanisms, this variant emerged as a genome-wide association study hit with extraordinary statistical significance³³ genome-wide association study hit with extraordinary statistical significance
P = 3.4×10⁻¹⁵ for coronary disease.

Lipoprotein(a), or Lp(a), is an LDL-like particle with an additional apolipoprotein(a) component⁴⁴ LDL-like particle with an additional apolipoprotein(a) component
making it structurally unique among lipoproteins. Unlike LDL cholesterol, which responds robustly to diet and statin therapy, Lp(a) levels are 70-90% genetically determined⁵⁵ 70-90% genetically determined
largely controlled by variation at the LPA locus on chromosome 6q26-27. The G allele at rs10455872 is associated with smaller apolipoprotein(a) isoforms and significantly elevated Lp(a) concentrations⁶⁶ smaller apolipoprotein(a) isoforms and significantly elevated Lp(a) concentrations
smaller isoforms are more atherogenic and thrombogenic.

The Mechanism

The rs10455872 variant sits within an intron and does not change the protein sequence, suggesting it affects gene expression or RNA processing⁷⁷ gene expression or RNA processing
possibly through regulatory elements or chromatin structure. The G allele correlates with reduced copy number of the kringle IV type 2 (KIV-2) repeats⁸⁸ reduced copy number of the kringle IV type 2 (KIV-2) repeats
resulting in smaller apolipoprotein(a) isoforms that are more efficiently synthesized and catabolized more slowly.

Elevated Lp(a) contributes to cardiovascular disease through multiple mechanisms⁹⁹ multiple mechanisms
atherosclerosis, inflammation, and thrombosis: it delivers cholesterol to arterial walls like LDL, carries pro-inflammatory oxidized phospholipids¹⁰¹⁰ pro-inflammatory oxidized phospholipids
bound to the kringle IV domains of apolipoprotein(a), and has anti-fibrinolytic effects¹¹¹¹ anti-fibrinolytic effects
its structural similarity to plasminogen allows it to compete with plasminogen and impair clot breakdown.

The Evidence

The association between rs10455872 and cardiovascular disease is among the strongest and most replicated in human genetics. Clarke et al. in the landmark 2009 NEJM study¹²¹² Clarke et al. in the landmark 2009 NEJM study
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. N Engl J Med 2009;361:2518-28 identified rs10455872 with an [odds ratio of 1.70 for coronary disease | 95% CI 1.49-1.95, one of the highest effect sizes for common variants]. When combined with another LPA variant (rs3798220), the odds ratio reached 4.87 for individuals with two or more risk alleles¹³¹³ odds ratio reached 4.87 for individuals with two or more risk alleles
indicating a gene-dose effect.

A 2014 prospective study in the EPIC-Norfolk cohort¹⁴¹⁴ 2014 prospective study in the EPIC-Norfolk cohort
following 17,553 participants for 11.7 years found that the G allele was associated not only with [coronary disease but also with aortic valve stenosis | OR 2.54 after adjusting for traditional risk factors], expanding our understanding of Lp(a) beyond coronary atherosclerosis to calcific valve disease. A Brazilian study of 1,394 patients undergoing coronary angiography¹⁵¹⁵ Brazilian study of 1,394 patients undergoing coronary angiography
validating the association in a different ethnic population confirmed the G allele doubled the odds of coronary lesions¹⁶¹⁶ G allele doubled the odds of coronary lesions
OR 2.02, and correlated with lesion severity scores.

A 2025 meta-analysis of 55,647 participants¹⁷¹⁷ 2025 meta-analysis of 55,647 participants
including 12,406 CHD cases and 17,321 controls for rs10455872 found the G allele associated with 1.6-fold increased coronary heart disease risk under multiple genetic models¹⁸¹⁸ 1.6-fold increased coronary heart disease risk under multiple genetic models
allelic OR 1.607, dominant OR 1.751.

The FOURIER trial analysis¹⁹¹⁹ FOURIER trial analysis
including 25,096 patients with established cardiovascular disease demonstrated that [patients with Lp(a) in the highest quartile had significantly higher coronary event rates | and derived greater absolute benefit from PCSK9 inhibition], providing evidence that lowering Lp(a) reduces cardiovascular risk.

Practical Implications

If you carry one or two G alleles, you have genetically elevated Lp(a) — a risk factor that operates independently of LDL cholesterol²⁰²⁰ independently of LDL cholesterol
meaning traditional cholesterol control may not eliminate your residual cardiovascular risk. The first step is measuring your serum Lp(a) level²¹²¹ measuring your serum Lp(a) level
a single measurement is sufficient since Lp(a) is highly stable over time. Current guidelines recommend screening Lp(a) once in all adults²²²² screening Lp(a) once in all adults
particularly those with premature cardiovascular disease, family history of heart disease, or recurrent events despite optimal LDL control.

Standard statins do not lower Lp(a)²³²³ Standard statins do not lower Lp(a)
and may modestly increase it in some individuals, though statins remain essential for LDL lowering. Niacin can reduce Lp(a) by 20-30%²⁴²⁴ Niacin can reduce Lp(a) by 20-30%
but has not shown cardiovascular benefit in outcome trials. The most effective currently available therapies are PCSK9 inhibitors (evolocumab, alirocumab)²⁵²⁵ PCSK9 inhibitors (evolocumab, alirocumab)
which lower Lp(a) by 20-27% in addition to dramatically lowering LDL, and lipoprotein apheresis²⁶²⁶ lipoprotein apheresis
which can reduce Lp(a) by 60-75% but requires twice-monthly extracorporeal treatments.

New RNA-based therapies specifically targeting apolipoprotein(a)²⁷²⁷ New RNA-based therapies specifically targeting apolipoprotein(a)
including antisense oligonucleotides and siRNA are in late-stage development and can reduce Lp(a) by 80-90% with periodic injections²⁸²⁸ reduce Lp(a) by 80-90% with periodic injections
potentially transforming treatment for those with very high levels.

Beyond medication, intensive LDL lowering takes on added importance²⁹²⁹ intensive LDL lowering takes on added importance
because the cardiovascular risk from Lp(a) and LDL are additive. Anti-inflammatory interventions may also help³⁰³⁰ Anti-inflammatory interventions may also help
since Lp(a) acts partly through inflammatory pathways. Lifestyle measures—regular aerobic exercise, Mediterranean diet, smoking cessation³¹³¹ regular aerobic exercise, Mediterranean diet, smoking cessation
the foundations of cardiovascular prevention—remain crucial, and aggressive management of all modifiable risk factors³²³² aggressive management of all modifiable risk factors
hypertension, diabetes, obesity becomes even more important when genetic risk is elevated.

Interactions

The rs10455872 variant interacts with rs3798220³³³³ rs3798220
another LPA variant in the kringle IV domain, and the two form three major haplotypes with combined effects on Lp(a) levels and cardiovascular risk³⁴³⁴ three major haplotypes with combined effects on Lp(a) levels and cardiovascular risk
combining both variants into a single genotype score predicts risk more accurately than either alone. Individuals carrying variant alleles at both positions face dramatically elevated risk³⁵³⁵ variant alleles at both positions face dramatically elevated risk
OR 4.87 compared to non-carriers.

The cardiovascular risk conferred by elevated Lp(a) is modified by concurrent LDL cholesterol levels³⁶³⁶ modified by concurrent LDL cholesterol levels
risk attenuates somewhat when LDL is very well controlled, but does not disappear. Other LPA variants including rs6415084 and rs12194138³⁷³⁷ rs6415084 and rs12194138
additional SNPs in the 5' region of the gene also influence Lp(a) levels and may compound effects when present together. Understanding the combined genetic burden across the LPA locus provides the most complete picture of inherited risk.